{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:04:04Z","timestamp":1780985044885,"version":"3.54.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoantibodies against Ro52 are not only detected in Sj\u00f6gren\u2019s disease (SjD), but also in idiopathic inflammatory myopathies, where they correlate with the incidence and severity of interstitial lung disease (ILD). It is still unclear whether antibodies against Ro52 are associated with further clinical manifestations in idiopathic inflammatory myopathies, as reduced tear and saliva production as a sign of associated SjD. Thus, this study aimed to determine the prevalence of objective SjD signs in Ro52-positive patients with idiopathic inflammatory myopathies, as well as the prevalence, characteristics, and clinical associations of ILD. A retrospective data analysis of patients from the Departments for Rheumatology, Nephrology, Neurology and Respiratory Medicine at Hannover Medical School, Germany was performed, in which a myositis immunoblot was determined between 2018 and 2024. Out of these patients, a total of 97 patients who were diagnosed with idiopathic inflammatory myopathy were included in the analysis. Overall, antibodies against Ro52 were detected in the myositis immunoblot in 46 of 97 patients (47%), whereas SSA antibodies were only detectable in 37 of 91 patients (41%) in the ELISA test. The detection of anti-Ro52 antibodies was associated with ILD (OR 3.5; p = 0.004). In addition, the presence of anti-Ro52 antibodies correlated with objective sicca symptoms, detected by reduced saliva and\/or tear production in the Saxon or Schirmer test (OR 6.3; p=0.026). This study revealed in patients with idiopathic inflammatory myopathies, anti-Ro52 antibodies are associated both with the occurrence of interstitial lung disease and with reduced saliva and tear production. Thus, they mark associated SjD in idiopathic inflammatory myopathy patients.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1841969","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:44:31Z","timestamp":1780983871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibodies against Ro52 in idiopathic inflammatory myopathies are associated with objective sicca symptoms"],"prefix":"10.3389","volume":"17","author":[{"given":"Anna","family":"Meinecke","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Hannover Medical School","place":["Hannover, Germany"]},{"name":"Program of Hannover Medical School for Clinician Scientists (PRACTIS) Clinician Scientist Program, Dean\u2019s Office for Academic Career Development, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Seeliger","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School","place":["Hannover, Germany"]},{"name":"German Center for Lung Research (DZL), Biomedical Research in End-Stage and Obstructive Lung Disease Hannover (BREATH)","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas C.","family":"Schupp","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School","place":["Hannover, Germany"]},{"name":"German Center for Lung Research (DZL), Biomedical Research in End-Stage and Obstructive Lung Disease Hannover (BREATH)","place":["Hannover, Germany"]},{"name":"Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)","place":["Hannover, Germany"]},{"name":"Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vega","family":"G\u00f6decke","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Therese","family":"Holzer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Systemic Inflammatory Diseases, III Department of Medicine, University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ernst","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-9-199505010-00010","article-title":"NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy","volume":"122","author":"Plotz","year":"1995","journal-title":"Ann Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"104804","DOI":"10.2139\/ssrn.4380064","article-title":"Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies","volume":"96","author":"Leclair","year":"2023","journal-title":"EBioMedicine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2019.07.006","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03368-9","article-title":"Clinical relevance of positively determined myositis antibodies in rheumatology: a retrospective monocentric analysis","volume":"26","author":"Schumacher","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13193080","article-title":"Detection of myositis autoantibodies by multi-analytic immunoassays in a large multicenter cohort of patients with definite idiopathic inflammatory myopathies","volume":"13","author":"Ghirardello","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11926-024-01171-8","article-title":"Newer autoantibodies and laboratory assessments in myositis","volume":"27","author":"Harvey","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2012.01.014","article-title":"The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review","volume":"39","author":"Oke","year":"2012","journal-title":"J Autoimmun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03382-x","article-title":"Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy","volume":"26","author":"Weng","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277007","article-title":"Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases","volume":"17","author":"Moll","year":"2022","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2025.05.036","article-title":"Association of anti-ro52 seropositive interstitial lung disease with a higher risk of disease progression and mortality","volume":"168","author":"Imai","year":"2025","journal-title":"Chest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00444","article-title":"Diagnostic utility of separate anti-ro60 and anti-ro52\/TRIM21 antibody detection in autoimmune diseases","volume":"10","author":"Robbins","year":"2019","journal-title":"Front Immunol"},{"key":"B14","first-page":"50","article-title":"Pathogenese und Diagnostik des Sj\u00f6gren-Syndroms","volume":"69","author":"Schmidt","year":"2009","journal-title":"Z Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 american college of rheumatology\/european league against rheumatism classification criteria for primary sj\u00f6gren's syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1055\/a-2017-8971","article-title":"Consensus guideline on the interdisciplinary diagnosis of interstitial lung diseases","volume":"77","author":"Kreuter","year":"2023","journal-title":"Pneumologie"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152407","article-title":"The differential role of SSa\/SSb and Ro52 antibodies in defining clinical phenotypes in idiopathic inflammatory myopathies","volume":"65","author":"Valle","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp\u2013002076","article-title":"Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis","volume":"10","author":"Nayebirad","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023998","article-title":"Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"8","author":"Kamiya","year":"2018","journal-title":"BMJ Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2402533","DOI":"10.1183\/13993003.02533\u20132024","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease","volume":"67","author":"Antoniou","year":"2026","journal-title":"Eur Respir J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/rhu.0000000000000365","article-title":"Clinical and prognostic factors associated with survival in mexican patients with idiopathic inflammatory myopathies","volume":"22","author":"Galindo-Feria","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.md.0000109755.65914.5e","article-title":"Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases","volume":"83","author":"Dank\u00f3","year":"2004","journal-title":"Med (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.12.1103","article-title":"Sicca symptoms and secondary Sj\u00f6gren's syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables","volume":"60","author":"Gilboe","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.974078","article-title":"Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis","volume":"13","author":"Giannini","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203305","article-title":"Primary Sjogren's syndrome and Malignancy risk: a systematic review and meta-analysis","volume":"73","author":"Liang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1115548","article-title":"Isolated anti-Ro52 identifies a severe subset of Sj\u00f6gren's syndrome patients","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102724","article-title":"Anti-Ro60 and anti-Ro52\/TRIM21: Two distinct autoantibodies in systemic autoimmune diseases","volume":"124","author":"Lee","year":"2021","journal-title":"J Autoimmun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa257","article-title":"Refining myositis associated with primary Sj\u00f6gren's syndrome: data from the prospective cohort ASSESS","volume":"60","author":"Felten","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1654576","article-title":"Idiopathic inflammatory myopathy associated with Sj\u00f6gren's disease: features of a distinct clinical entity","volume":"16","author":"Konen","year":"2025","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.11.009","article-title":"Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020","volume":"51","author":"Sun","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01105-9","article-title":"Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups","volume":"20","author":"Giannini","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/art.41964","article-title":"Performance of the 2017 european alliance of associations for rheumatology\/american college of rheumatology classification criteria for idiopathic inflammatory myopathies in patients with myositis-specific autoantibodies","volume":"74","author":"Casal-Dominguez","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1841969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:44:32Z","timestamp":1780983872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1841969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1841969"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1841969","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1841969"}}